Boston Scientific Announces Favorable Court Ruling Dismissing Securities Fraud Case

Boston Scientific Corporation BSX today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the recall of the Company's TAXUS® Express2 Paclitaxel-Eluting Coronary Stent System in 2004. The case, which had been filed by the Mississippi Public Employees' Retirement System, had previously been dismissed by the U.S. District Court for the District of Massachusetts. "We are pleased with the Court's decision," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific. "The Company has made significant progress in reducing its legal exposure in the last 24 months and will continue to vigorously defend itself against allegations of this type."